Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe standard and novel approaches using endocrine therapy for the treatment of early breast cancer
- Discuss treatment strategies for premenopausal and postmenopausal early breast cancer patients
- Employ risk-assessment strategies for guiding treatment choices for patients with early breast cancer
- Identify patient behaviors that may complicate the compliance and treatment of early breast cancer
- Nurses will be better able to provide appropriate care and counsel for patients and their families
Topics covered include:
- Introduction
- TEAM Trial: Upfront vs Sequential Use of Aromatase Inhibitors
- IES: Tamoxifen Followed by Switching to an AI vs Continuing Tamoxifen
- Risk Model to Predict Benefit From Tamoxifen vs AI Therapy
- Single Nucleotide Polymorphisms Linked to AI-Induced Musculoskeletal Adverse Events
- Extended AI Following Tamoxifen in Premenopausal Women
- CYP2D6 Activity and Tamoxifen Outcomes
- Nonadherence to Adjuvant Hormonal Therapy
- The Relationship Between Breast Cancer Incidence and Bisphosphonates
- Survival Benefit of Trastuzumab With Both Anthracycline- and Nonanthracycline-Based Chemotherapy
- N9831: Concurrent vs Sequential Trastuzumab
- SWOG 8814: 21-Gene Recurrence Score for Predicting Chemotherapy Benefit
- Neoadjuvant Bevacizumab in Patients With Triple-Negative Breast Cancer
- Obesity as a Prognostic Factor in Early Breast Cancer Patients
- Conclusions
Abstract